Skip to main content
. 2016 Jan 21;39:323–333. doi: 10.1007/s40264-015-0384-7

Table 3.

Other symptoms/events reported captured as free-text events and presented as MedDRA® preferred term (% of total other events reported)

System organ class (SOC) PT n (%)
Infections and infestations Nasopharyngitis 2 (5.7)
Tonsillitis 1 (2.9)
Urinary tract infection 1 (2.9)
Hordeolum 1 (2.9)
Influenza 1 (2.9)
Psychiatric disorders Mood altered 1 (2.9)
Nervous system disorders Dizziness 1 (2.9)
Lethargy 1 (2.9)
Migraine 1 (2.9)
Ear and labyrinth disorders Cerumen impaction 1 (2.9)
Ear pain 1 (2.9)
Gastrointestinal disorders Diarrhoea 4 (11.4)
Mouth ulceration 2 (5.7)
Abdominal pain upper 1 (2.9)
Anal inflammation 1 (2.9)
Chapped lips 1 (2.9)
Dysphagia 1 (2.9)
Skin and subcutaneous tissue disorders Pruritus 1 (2.9)
Blister 1 (2.9)
Musculoskeletal and connective tissue disorders Growing pains 1 (2.9)
Reproductive system and breast disorders Vulvovaginal rash 1 (2.9)
General disorders and administration site conditions Fatigue 7 (20.0)
Irritability 1 (2.9)
Adverse drug reaction 1 (2.9)
Total 35 (100.0)

PT preferred term